SCM
KLRS

Stonepine Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Stonepine Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
30,122
+9,722
+48% +$50.5K 0.07% 82
2026
Q1 		$118K Buy
+20,400
New +$181K 0.05% 78

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stonepine Capital Management's KLRS Position: Q2 2026 in Review

Stonepine Capital Management increased its Kalaris Therapeutics (KLRS) stake by 48% in Q2 2026, buying an estimated $50.5K and bringing the position to 30,122 shares worth $123K. The position accounts for 0.07% of the portfolio, ranked #82.

Stonepine Capital Management first reported a position in KLRS in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Stonepine Capital Management held 30,122 shares of Kalaris Therapeutics worth $123K as of Q2 2026.
  • Stonepine Capital Management bought 9,722 Kalaris Therapeutics shares in Q2 2026, an estimated $50.5K.
  • Kalaris Therapeutics made up 0.07% of Stonepine Capital Management's portfolio in Q2 2026, its #82 holding.
  • Stonepine Capital Management first reported a position in Kalaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.